Showing 3461-3470 of 5621 results for "".
- Hoya Launches VisuPro Advanced Focus Spectacle Lenses for Patients Experiencing Early Symptoms of Presbyopiahttps://modernod.com/news/hoya-launches-visupro-advanced-focus-spectacle-lenses-for-patients-experiencing-first-symptoms-of-presbyopia/2482724/Hoya has launched its VisuPro All Day and VisuPro Flex advanced focus spectacle lenses, which are designed to help people in their late 30s to mid-40s that are beginning to experience presbyopia. As people enter this age group, they may begi
- Alcon Acquires Majority Interest in Aurion Biotechhttps://modernod.com/news/alcon-acquires-majority-interest-in-aurion-biotech-to-advance-cell-therapy-for-corneal-endothelial-disease/2482718/Alcon announced it has acquired a majority interest in Aurion Biotech, a clinical-stage company developing cell therapies to treat eye diseases. Financial terms of the deal were not disclosed.
- Surrozen Discontinues Liver Program; Shifts Focus to Ophthalmologyhttps://modernod.com/news/surrozen-discontinues-liver-program-shifts-focus-to-ophthalmology/2482716/Surrozen announced that the company will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ophthalmology programs, including development of new treatment options for retinopathies. The company will use a $175-million private placement
- Alcon Boosts Femtosecond Laser Portfolio with Acquisition of Lensarhttps://modernod.com/news/alcon-boosts-femtosecond-laser-technology-with-acquisition-of-lensar/2482713/Alcon and Lensar have entered into a definitive merger agreement through which Alcon intends to acquire Lensar for about $356 million. The acquisition includes ALLY Robotic Cataract Laser Treatment System, Lensar’s proprietary Streamline software technology, and Lensar
- Unity Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in DMEhttps://modernod.com/news/unity-biotechnology-announces-topline-results-from-the-aspire-phase-2b-study-in-dme/2482712/Unity Biotechnology announced topline results from the phase 2b ASPIRE clinical trial of intravitreal UBX1325 in patients with diabetic macular edema (DME) who had poor vision despite prior anti-VEGF treatment. The study results include data from all patients through 24 weeks, and the majori
- Prevent Blindness Announces Matt MacDonald as Chair-Elect of Board of Directorshttps://modernod.com/news/prevent-blindness-announces-matt-macdonald-as-chair-elect-of-board-of-directors/2482708/Prevent Blindness, a nonprofit organization dedicated to eye health and safety awareness, named Matt MacDonald as Chair-elect of its Board of Directors. The vote was held last week during the Spring 2025 Board Meeting. He will succeed current Board of Directors Chair Jim McGrann, CEO of Adva
- Iantrek Announces Positive Efficacy and Safety Profile of its Bio-Interventional Technologyhttps://modernod.com/news/iantrek-announces-positive-efficacy-and-safety-profile-of-its-bio-interventional-technology-to-enhance-uveoscleral-outflow-in-glaucoma-patients/2482707/Iantrek Corporation today announced positive results from its 2-year prospective clinical study evaluating its bio-reinforced cyclodialysis technology. The study, published in Ophthalmology Science, affirms the safety and efficacy of Iantrek’s bio-interventional technology to enhance&n
- Bausch + Lomb Launches Arise Orthokeratology Lens System in the UShttps://modernod.com/news/bausch-lomb-announces-arisetm-orthokeratology-lens-system-in-the-united-states/2482702/Bausch + Lomb announced the US launch of Arise, a lens fitting system designed to use intelligent, cloud-based technology to streamline the orthokeratology lens design process. Orthokeratology is a non-surgical method of vision correction that uses rigid, gas-permea
- Study Finds Most Glaucoma Patients Unaware of Preservative-Free Treatment Optionshttps://modernod.com/news/60-of-glaucoma-patients-unaware-of-preservative-free-treatment-options-study-from-preservative-freedom-coalition/2482698/The Preservative Freedom Coalition announced the results of a new nationwide survey delving into the experience of glaucoma patients to identify opportunities for improved communication with their eye care providers. This comes as Monday kicked o
- First Patients Enrolled in 4DMT's Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMDhttps://modernod.com/news/first-patients-enrolled-in-4dmts-phase-3-clinical-trial-evaluating-4d-150-in-wet-amd/2482694/4D Molecular Therapeutics (4DMT) announced that the first patients have been enrolled across multiple sites in the 4FRONT-1 phase 3 clinical trial evaluating 4D-150 for the treatment of wet age-related macular degeneration (AMD). "This is a historic moment for 4DMT as we becom